Organization
Forma Therapeutics
10 clinical trials
Clinical trial
A Pilot Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell DiseaseStatus: Not yet recruiting, Estimated PCD: 2025-06-15
Clinical trial
A Phase 1/2, Multicenter, Open-label Study of FT-2102 as a Single Agent and in Combination With Azacitidine or Cytarabine in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome With an IDH1 MutationStatus: Completed, Estimated PCD: 2023-12-28
Clinical trial
A Phase 2 Open-Label Study to Evaluate Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Phase 2 Open-Label Study to Evaluate Safety and Clinical Activity of Etavopivat in Patients With Thalassemia or Sickle Cell DiseaseStatus: Recruiting, Estimated PCD: 2025-11-03
Clinical trial
A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary StrokeStatus: Recruiting, Estimated PCD: 2025-01-31
Clinical trial
An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral Etavopivat, a Pyruvate Kinase Activator in Patients With Sickle Cell Disease (HIBISCUS)Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Randomized, Placebo-controlled, Double Blind, Single Ascending and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of FT-4202 in Healthy Volunteers and Sickle Cell Disease PatientsStatus: Completed, Estimated PCD: 2021-12-17
Clinical trial
A Single Arm, Open Label, Phase 1/2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell DiseaseStatus: Recruiting, Estimated PCD: 2026-01-20
Clinical trial
A Phase 1/1b Dose Escalation, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of FT-1101 as a Single Agent and in Combination With Azacitidine in Patients With Relapsed or Refractory Hematologic MalignanciesStatus: Completed, Estimated PCD: 2019-03-01
Clinical trial
A Phase 1b/2 Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 MutationStatus: Completed, Estimated PCD: 2021-05-24